- Conditions
- Cataracts
- Interventions
- DisCoVisc, DuoVisc, BioVisc, Healon5, Amvisc Plus
- Device
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 49 Years and older
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 553–576
of 669
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cataract
- Interventions
- Not listed
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 399 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Cataract
- Interventions
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac Ophthalmic Suspension, 0.1%, Nepafenac Vehicle 0.3%
- Drug · Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,342 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Ocular Inflammation and Pain After Cataract Surgery
- Interventions
- APP13007, 0.05%, APP13007, 0.1%, APP13007 Placebo, 0.05%, APP13007 Placebo, 0.1%
- Drug
- Lead sponsor
- Formosa Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Inglewood, California • Rancho Cordova, California + 5 more
- Conditions
- End Stage Renal Disease
- Interventions
- Venography, Intravascular ultrasound (IVUS), Image processing
- Diagnostic Test · Other
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Refractive Surgery
- Interventions
- Wave-Front Optimized (WFO) ablation vs Topography-guided (TG) ablation
- Device
- Lead sponsor
- 59th Medical Wing
- Federal
- Eligibility
- 21 Years to 50 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Unstable Corneas
- Interventions
- Epithelium-On Riboflavin, Epithelium-Off Riboflavin, UV Light - Continuous Beam, UV Pulsed Beam
- Drug · Device
- Lead sponsor
- Crowd Health Research, LTD
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2014
- U.S. locations
- 16
- States / cities
- Santa Rosa, California • Denver, Colorado • Jacksonville, Florida + 13 more
- Conditions
- Glaucoma Following Surgery
- Interventions
- DEXTENZA, Topical Dexamethasone
- Drug
- Lead sponsor
- Brian Jerkins, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Glaucoma, Open-Angle
- Interventions
- OMNI® Surgical System
- Device
- Lead sponsor
- Sight Sciences, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 11
- States / cities
- Fayetteville, Arkansas • Newport Beach, California • Petaluma, California + 8 more
- Conditions
- Aphakia, Astigmatism, Presbyopia
- Interventions
- Clareon Vivity IOL - Non Toric, Clareon Vivity IOL - Toric, Clareon PanOptix Trifocal IOL - Non Toric, Clareon PanOptix Trifocal IOL - Toric
- Device
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 6
- States / cities
- Torrance, California • Jacksonville, Florida • Liverpool, New York + 3 more
- Conditions
- Glaucoma
- Interventions
- Tube shunt surgery, Trabeculectomy, Mitomycin C
- Procedure · Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2021
- U.S. locations
- 12
- States / cities
- Sacramento, California • Gainesville, Florida • Miami, Florida + 9 more
- Conditions
- Upper Eyelid Surgery
- Interventions
- Hyaluronidase, 2 mL of lidocaine 2% with epinephrine 1:100,000 without rHuPH20
- Drug · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Ocular Infection
- Interventions
- DCN01, Unisol
- Drug
- Lead sponsor
- Deacon Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Vitreoretinal Surgery, Ocular Inflammation, Post-operative Pain, Post-Operative Inflammation
- Interventions
- Dexamethasone Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Aphakia, Astigmatism
- Interventions
- Clareon TruPlus Monofocal Non-Toric IOL, Clareon TruPlus Monofocal Toric IOL, Phacoemulsification
- Device · Procedure
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Brecksville, Ohio • Mt. Pleasant, South Carolina + 2 more
- Conditions
- Intraocular Retinoblastoma
- Interventions
- Carboplatin, Cryosurgery, Infrared Laser Therapy, Iodine I-125, Radiation Therapy, Ruthenium Ru-106, Vincristine Sulfate
- Drug · Procedure · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 5 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2017
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 6 more
- Conditions
- Primary Open Angle Glaucoma
- Interventions
- Cataract surgery combined with ab-interno canaloplasty utililzing the iTrack Advance canaloplasty device, Cataract surgery
- Device · Procedure
- Lead sponsor
- Nova Eye, Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Sugar Land, Texas
- Conditions
- Cataract
- Interventions
- Nepafenac Ophthalmic Suspension, 0.1%
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Nacogdoches, Texas
- Conditions
- Surgery, Myopia
- Interventions
- Wavefront optimized LASIK, Wavefront optimized Photorefractive Keratectomy, Topography-guided LASIK, Topography-guided Photorefractive Keratectomy
- Device
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Murray, Utah
- Conditions
- Cleft Lip and Palate
- Interventions
- Comparator: Retrospective Group(Control), Prospective Group
- Other · Device
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- Up to 6 Months
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cataracts
- Interventions
- Cataract Refractive Suite (CRS), Standard manual technique
- Device · Procedure
- Lead sponsor
- Alcon, a Novartis Company
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 3
- States / cities
- Panama City, Florida • Stillwater, Minnesota • Hurst, Texas
- Conditions
- Amblyopia, Strabismus
- Interventions
- Binocular Treatment, Sham Binocular Treatment
- Procedure
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Intraocular Pressure
- Interventions
- Not listed
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Inflammation
- Interventions
- Difluprednate, Placebo
- Drug
- Lead sponsor
- Sirion Therapeutics, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 219 participants
- U.S. locations
- 1
- States / cities
- Washington, Missouri